The Christie Research Publications Repository

The repository contains the research outputs from staff and students at The Christie NHS Foundation Trust and Cancer Research UK Manchester Institute.

Current Repository Content:

Over 7000 peer reviewed articles, reviews and selected publications from 1933 onwards.

Find out more…

We upload data monthly to the repository. To find out more about the repository, article submission or for advice on how to search it:

Please contact The Christie Library and Knowledge Service at the-christie.library@nhs.net.

Recent Submissions

  • ItemOpen Access
    Procedures of data merging in precision cancer medicine: the PRIME-ROSE project
    (2026) Van der Pol, H.; Kringelbach, T.; Martin Agudo, M.; Bratseth Stav, G.; Fagereng, G. L.; Fiocco, M.; Sørum Falk, R.; Homer, V.; Haj Mohammad, S.; Timmer, H.; Verlingue, L.; Helland, Å.; Rohrberg, K.; Lassen, U.; Halford, S.; Jalkanen, K.; Juslin, T.; Krebs, M. G.; Oliveira, J.; Baltruskeviciene, E.; Ojamaa, K.; Taskén, K.; Gelderblom, H.; The Christie NHS Foundation Trust, Manchester, United Kingdom.
    BACKGROUND AND PURPOSE: As more interventional clinical trials in Precision Cancer Medicine (PCM) are introduced, molecular descriptions of tumours have led to multiple subtypes, even within common tumour types. Therefore, the main limitation of these trials is the small number of eligible patients to assess the clinical benefit. The PRIME-ROSE project addresses this limitation by pooling data from multiple European Drug Rediscovery Protocol (DRUP)-like clinical trials, such that slowly accruing cohorts are accelerated. To achieve this task, a well-documented commonly approved procedure for data merging needs to be established. Patient/material and methods: Data sharing is achievable when there is an organisation that includes people from different disciplines who can navigate institutional and country-specific information and governance requirements. Furthermore, alignment of all the study procedures are needed before data are shared. Next, the process of merging data requires harmonisation and standardisation. Implementation of the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) facilitates future data aggregation. RESULTS: By aggregating data from European DRUP-like clinical trials, cohorts are completed that were unable to do so in stand-alone studies. Since initiation, the PRIME-ROSE project monitors over 300 cohorts across more than 20 treatments encompassing over 1,000 patients. At least 20 cohorts have progressed after interim analysis. INTERPRETATION: Data sharing across European trials is feasible and enhances the advancements of PCM studies. The methodologies developed in the PRIME-ROSE project provide a foundation for future data integration efforts in PCM clinical trials, underscoring the viability of conducting robust trials in a global context.
  • ItemOpen Access
    Informative censoring in maintenance therapy trials for advanced ovarian cancer: an empirical assessment of its impact on treatment benefit
    (2026) Woodford, R.; Lord, S.; Decaria, A.; Simes, J.; Friedlander, M.; Marschner, I. C.; Lee, C. K.; The Christie NHS Foundation Trust, Manchester, United Kingdom.
    INTRODUCTION: A considerable proportion of patients in ovarian cancer maintenance trials may be censored in progression-free survival (PFS) analyses, the primary study endpoint. Such censoring is often informative, reflecting discontinuation due to toxicity, preference, or early switch to alternative therapies, potentially biasing results toward overestimating PFS benefit. We aimed to quantify the impact of informative censoring on PFS in these trials. METHODS: Double-blind, placebo-controlled maintenance therapy trials were selected, and individual patient data reconstructed from published survival curves. A sensitivity analysis reclassified varying proportions of all censored events as progressions to model scenarios from 0 % to 100 % informative censoring. Hazard ratios (HRs) were re-estimated and compared with the originally reported values. Duration of therapy was compared with PFS. RESULTS: Twenty-two trial units (N = 8256) were included. Nineteen reported statistically significant results, falling to 14 (74 %) at the upper limit of analysis. HRs diminished progressively, with a 6 % reduction at 10 % censoring and 29 % at 100 %. In nine PARP inhibitor trials, treatment duration was shorter than PFS (mean of medians = 12.5 vs 17.6 months). Results were consistent when limited to PARP inhibitor studies. No correlation was observed between adverse events and censoring. CONCLUSIONS: Informative censoring can substantially distort PFS benefit estimates in ovarian cancer maintenance trials. Transparent reporting of censoring rates and their causes is essential for meaningful clinical interpretation and should be standard in all randomised maintenance therapy trials.
  • ItemOpen Access
    Selecting first-line immunotherapy in advanced melanoma: current evidence on efficacy across diverse patient populations
    (2025) Kreft, S.; Bosetti, T.; Lee, R.; Lorigan, P.; The Christie NHS Foundation Trust, Manchester, United Kingdom.
    Immunotherapy has dramatically changed the outcome for patients with advanced melanoma, with significant improvements in overall survival and potential cure for some. The recent approval of nivolumab in combination with relatlimab (nivolumab-relatlimab) added a third immunotherapy option for first-line treatment for advanced melanoma. Nivolumab-relatlimab has shown greater efficacy compared to single-agent nivolumab and has fewer unacceptable side effects compared to the combination of ipilimumab and nivolumab (ipilimumab-nivolumab). However, the lack of both long-term follow-up data and direct comparison with ipilimumab-nivolumab raises uncertainty about where to position nivolumab-relatlimab in clinical practice. Since most patients who respond to combination ipilimumab-nivolumab also respond to nivolumab-relatlimab, and many to single-agent anti-programmed death-1 (PD-1) monotherapy, the challenge is to identify the subgroup of patients who need ipilimumab-nivolumab and would not achieve similar benefits from less toxic alternatives. This review discusses the available data on efficacy of the three approved first-line immunotherapies (single-agent anti-PD-1, nivolumab-relatlimab or ipilimumab-nivolumab) and their value in distinct population groups to help guide clinical decisions.
  • ItemOpen Access
    Posterior reversible encephalopathy syndrome (PRES) following fruquintinib in a normotensive patient with metastatic colorectal cancer: a case report
    (2025) ElManfalouty, R.; Holayel, A.; Russell, I.; Marti, K.; The Christie NHS Foundation Trust, Manchester, United Kingdom.
    We report a rare case of posterior reversible encephalopathy syndrome (PRES) following fruquintinib treatment in a 71-year-old female with metastatic colorectal adenocarcinoma harbouring a KRAS G12D mutation. The patient had previously undergone multiple lines of chemotherapy and surgical resections with stable disease before receiving fruquintinib under compassionate access. After two cycles, she developed headaches and acute encephalopathy. MRI confirmed PRES without associated hypertension. Fruquintinib was discontinued, and the patient made a full neurological recovery. This case highlights a rare but significant toxicity of anti-vascular endothelial growth factor (VEGF) therapy in the colorectal cancer setting and underscores the importance of early radiological evaluation in suspected PRES.
  • ItemOpen Access
    Disparity in cancer screening among black and other ethnic minority groups in the UK
    (2026) Iyizoba-Ebozue, Z.; Njoku, K.; Fatimilehin, A.; Mbanu, P.; Adeleke, S.; The Christie NHS Foundation Trust, Manchester, United Kingdom.
Show more

Communities in Christie

Select a community to browse its collections.